Latest On Northwest Biotherapeutics, Inc (NWBO):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-04-30 04:21 EST | News | Northwest Bio: Data Is Great, But Nothing Else Is | N/A |  |
| 2023-03-21 15:35 EST | News | Northwest Biotherapeutics, Advent get license for cell therapy facility in UK | N/A | |
| 2023-03-09 12:08 EST | News | Northwest Bio in $11M loan agreement with Streeterville Capital | N/A | |
| 2023-02-12 13:10 EST | News | Northwest Bio: No BLA Date, And A Major Lawsuit | N/A | |
| 2022-11-23 08:13 EST | News | Northwest Biotherapeutics: Data Is Done, Just Wait For Approval | N/A | |
| 2022-11-17 16:22 EST | News | Northwest achieves positive phase 3 results for glioblastoma candidate; shares rise 24% | N/A | |
| 2022-10-18 14:36 EST | News | Northwest Biotherapeutics: Biopharma's Promising Delinquent | N/A | |
| 2022-08-08 17:11 EST | News | Northwest Biotherapeutics: Another Quarter Of Silence | N/A | |
| 2022-05-22 09:04 EST | News | Northwest Bio: Buy Again, Wait For Regulatory Process | N/A | |
| 2022-05-10 21:55 EST | News | Northwest Bio plunges after late-stage data for lead candidate in brain cancer | N/A | |
| 2022-03-06 03:57 EST | News | Northwest Bio: What A Comparison Analysis Says About Its Progress | N/A | |
| 2022-02-18 07:43 EST | News | Northwest stock rises 9% as company begins cancer vaccine production at UK facility | N/A | |
| 2021-12-20 02:07 EST | News | Northwest Biotherapeutics: No TLD Yet | N/A | |
| 2021-11-29 22:22 EST | News | Northwest Biotherapeutics secures $15M financing on stock purchase rights | N/A | |
| 2021-10-13 15:41 EST | News | Northwest Bio: Nowhere To Go But Up | N/A | |
| 2021-07-22 17:24 EST | News | Northwest Bio gaining attention as investors await phase 3 GBM data | N/A | |
| 2021-07-22 17:24 EST | News | Northwest Biotherapeutics: CEO Says Unblinding Is A Work In Progress | N/A | |
| 2021-03-11 01:36 EST | News | Northwest Bio: The Endgame Is Approaching | N/A | |
| 2021-01-16 06:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-21 03:16 EST | News | Northwest Biotherapeutics: Blinded By The Dazzle Of The Unblinding | N/A | |
| 2020-12-04 06:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-09 20:09 EST | News | Northwest Bio, Wow! | N/A | |
| 2020-10-08 21:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-06 02:17 EST | News | Northwest Biotherapeutics locks Phase 3 data from brain tumor study | N/A | |
| 2020-10-04 15:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 09:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-02 05:28 EST | News | Northwest Biotherapeutics high on Flaskworks acquisition | N/A | |
| 2020-08-21 13:55 EST | News | Northwest Biotherapeutics secures loan financing of $5M | N/A | |
| 2020-08-14 12:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-13 07:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-12 07:37 EST | News | Northwest Biotherapeutics reports Q2 results | N/A | |
| 2020-08-12 07:36 EST | News | Northwest Biotherapeutics secures capital raise of $8M | N/A | |
| 2020-08-06 16:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 12:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 16:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 21:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-17 09:32 EST | News | Denovo Biopharma's enzastaurin Fast Track'd for brain tumor | N/A | |
| 2020-07-09 12:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 07:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-03 07:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-02 23:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-02 07:15 EST | Financials | Company financials have been released. | Neutral | |
About Northwest Biotherapeutics, Inc (NWBO):
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L that is in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, which is in Phase I/II clinical trials to treat various inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
General
- Name Northwest Biotherapeutics, Inc
- Symbol NWBO
- Type Common Stock
- Exchange OTCQB
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 17
- Last Split Factor1:16
- Last Split Date2012-09-26
- Fiscal Year EndDecember
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.nwbio.com
View More
Valuation
- Trailing PE 81.98
- Price/Sales (Trailing 12 Mt.) 541.99
- Enterprise Value Revenue 672.65
- Enterprise Value EBITDA 39.16
View More
Financials
- Most Recent Quarter 2020-09-30
- Operating Margin -4122%
- Return on Assets -232%
- Revenue 1.69 million
- Earnings Per Share $0.01
- Revenue Per Share $0
- Gross Profit -11180000
- Quarterly Earnings Growth -63.6%
View More
Highlights
- Market Capitalization 1.29 billion
- EBITDA -29413000
- Analyst Target Price $5
- Book Value Per Share -$0.09
View More
Share Statistics
- Shares Outstanding 822.72 million
- Shares Float 791.91 million
- % Held by Insiders 396%
- % Held by Institutions 0.03%
- Shares Short 14.14 million
- Shares Short Prior Month 13.83 million
- Short Ratio 13.54
- Short % of Float 15%
- Short % of Shares Outstanding 11%
View More
Technicals
- Beta 0.72
- 52 Week High $2.51
- 52 Week Low $0.14
- 50 Day Moving Average 1.51
- 200 Day Moving Average 1.29
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Northwest Biotherapeutics, Inc (NWBO) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Northwest Biotherapeutics, Inc (NWBO) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-19 | $216000 | -$0.26 | ||
| 2020-06-30 | 2020-09-30 | $N/A | -$0.26 | ||
| 2020-03-31 | 2020-06-30 | $570000 | -$0.08 | ||
| 2019-12-31 | 2020-03-31 | $897000 | $0.00 | ||
| 2019-09-30 | 2019-12-31 | $593000 | $0.01 | ||
| 2019-06-30 | 2019-09-30 | $581000 | -$0.01 | ||
| 2019-03-31 | 2019-06-30 | $339000 | $0.00 | ||
| 2018-12-31 | 2019-03-31 | $451000 | -$0.04 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $453000 | -$0.01 | ||
| 2018-06-30 | 2018-09-30 | $278000 | $0.02 | ||
| 2018-03-31 | 2018-06-30 | $132000 | -$0.06 | ||
| 2017-12-31 | 2018-03-31 | $32000 | -$0.09 | ||
| 2017-09-30 | 2017-12-31 | $148000 | -$0.09 | ||
| 2017-06-30 | 2017-09-30 | $88000 | -$0.08 | ||
| 2017-03-31 | 2017-06-30 | $68000 | -$0.05 | -$0.19 | 74.11% |
| 2016-12-31 | 2017-03-31 | $71000 | -$0.08 | ||
| 2016-09-30 | 2016-11-10 | $159000 | -$0.25 | -$0.12 | -112% |
| 2016-06-30 | 2016-08-09 | $157000 | -$0.20 | -$0.29 | 31.1% |
| 2016-03-31 | 2016-05-11 | $236000 | -$0.06 | -$0.25 | 76% |
| 2015-12-31 | 2016-03-16 | $863000 | -$0.62 | -$0.27 | -128.93% |
| 2015-09-30 | 2015-11-09 | $291000 | $0.25 | ||
| 2015-06-30 | 2015-08-10 | $391000 | -$0.88 | ||
| 2015-03-31 | 2015-05-11 | $194000 | -$0.67 | ||
| 2014-12-31 | 2015-03-17 | $872000 | -$0.65 | ||
| 2014-09-30 | 2014-11-19 | $582000 | -$0.35 | ||
| 2014-06-30 | 2014-08-15 | $N/A | -$0.45 | ||
| 2014-03-31 | 2014-04-01 | $N/A | -$0.40 | -$0.41 | 2.44% |
| 2013-12-31 | 2014-03-31 | $N/A | -$0.40 | -$0.41 | 2.44% |
| 2013-09-30 | 2013-11-15 | $400000 | -$0.65 | -$0.32 | -103.13% |
| 2013-06-30 | 2013-08-15 | $272000 | -$0.40 | ||
| 2013-03-31 | 2013-05-16 | $137000 | -$0.54 | ||
| 2012-12-31 | 2013-02-27 | $322000 | -$2.60 | ||
| 2012-09-30 | 2012-11-20 | $120000 | -$1.50 | ||
| 2012-06-30 | 2012-08-14 | $330000 | -$1.00 | ||
| 2012-03-31 | 2012-05-18 | $N/A | -$1.06 | ||
| 2011-12-31 | 2012-02-29 | $N/A | -$2.14 | ||
| 2011-09-30 | 2011-11-22 | $10000 | $0.06 | ||
| 2011-06-30 | 2011-08-16 | $N/A | -$2.35 | ||
| 2011-03-31 | 2011-05-20 | $N/A | -$1.75 | ||
| 2010-12-31 | 2011-03-02 | $N/A | -$2.18 | ||
| 2010-09-30 | 2010-11-23 | $10000 | -$0.83 | ||
| 2010-06-30 | 2010-08-17 | $N/A | -$2.19 | ||
| 2010-03-31 | 2010-05-21 | $N/A | -$1.56 | ||
| 2009-12-31 | 2010-03-03 | $N/A | -$1.63 | ||
| 2009-09-30 | 2009-11-23 | $10000 | -$4.33 | ||
| 2009-06-30 | 2009-08-14 | $N/A | -$1.45 | ||
| 2009-03-31 | 2009-05-15 | $N/A | -$1.69 | ||
| 2008-12-31 | 2009-02-25 | $N/A | -$1.97 | ||
| 2008-09-30 | 2008-12-03 | $10000 | -$2.04 | ||
| 2008-06-30 | 2008-08-20 | $N/A | -$2.28 | ||
| 2008-03-31 | 2008-05-16 | $N/A | -$2.13 | ||
| 2007-09-30 | 2007-11-28 | $10000 | -$1.48 | ||
| 2007-06-30 | 2007-08-20 | $N/A | -$89.01 | ||
| 2007-03-31 | 2007-05-30 | $N/A | -$7.18 | ||
| 2006-12-31 | 2007-02-28 | $N/A | -$9.24 | ||
| 2006-09-30 | 2006-11-29 | $80000 | -$6.65 | ||
| 2006-06-30 | 2006-08-30 | $N/A | $6.75 | ||
| 2006-03-31 | 2006-05-31 | $N/A | -$49.40 | ||
| 2005-12-31 | 2006-03-01 | $14000 | -$25.00 | ||
| 2005-09-30 | 2005-11-30 | $15000 | -$35.00 | ||
| 2005-06-30 | 2005-08-31 | $8000 | -$33.19 | ||
| 2005-03-31 | 2005-06-01 | $87000 | -$31.85 | ||
| 2004-12-31 | 2005-03-02 | $56000 | -$55.20 | ||
| 2004-09-30 | 2004-12-01 | $91000 | -$28.58 | ||
| 2004-06-30 | 2004-09-01 | $116000 | -$12.85 | ||
| 2004-03-31 | 2004-06-02 | $127000 | -$10.45 | ||
| 2003-12-31 | 2004-03-03 | $128000 | -$9.60 | ||
| 2003-09-30 | 2003-12-03 | $145000 | -$14.98 | ||
| 2003-06-30 | 2003-09-03 | $187000 | -$26.65 | ||
| 2003-03-31 | 2003-05-28 | $69000 | -$20.47 | ||
| 2002-12-31 | 2003-03-19 | $N/A | -$24.00 | -$50.40 | 52.38% |
| 2002-09-30 | 2002-11-07 | $N/A | -$50.40 | -$56.40 | 10.64% |
| 2002-06-30 | 2002-08-28 | $6000 | -$63.20 | ||
| 2002-03-31 | 2002-05-29 | $3000 | -$44.47 |
Northwest Biotherapeutics, Inc (NWBO) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | 3.76 million | 3.89 million | 3.41 million |
| Income Before Tax | -194.1 million | N/A | 2.73 million | 6.67 million | -6.24 million |
| Selling General Administrative | N/A | N/A | 4.55 million | 3.62 million | 3.64 million |
| Gross Profit | -47.88 million | N/A | N/A | 10.6 million | -6.46 million |
| Ebit | -194.1 million | N/A | 3.45 million | 7.38 million | -5.3 million |
| Operating Income | -47.88 million | N/A | -7.73 million | -6.6 million | -6.46 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | 216000 | N/A | 570000 | 897000 | 593000 |
| Cost of Revenue | 48.09 million | N/A | N/A | -9.7 million | 7.05 million |
| Total Other Income Expense Net | N/A | N/A | 11.08 million | 13.99 million | 938000 |
| Net Income From Continuing Operations | -194.1 million | N/A | 2.73 million | 6.67 million | -6.24 million |
| Net Income Applicable to Common Shares | -194.1 million | -57.95 million | 2.9 million | 6.67 million | -6.24 million |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | -62000 | -114000 | -21000 | -61000 |
| Change to Liabilities | 460000 | 1.19 million | 22000 | 1.04 million | -2.86 million |
| Total Cash Flow from Investing Activities | -1.24 million | -62000 | -114000 | -21000 | -61000 |
| Net Borrowings | 3.46 million | 1.18 million | 500000 | -1.4 million | -1.5 million |
| Total Cash Flow from Financial Activities | N/A | 7.03 million | 5.13 million | 850000 | 29000 |
| Change to Operating Activities | 634000 | -43000 | 165000 | -448000 | -61000 |
| Change in Cash | N/A | 392000 | -1.6 million | -4.71 million | -9.61 million |
| Total Cash from Operating Activities | -6.33 million | -7.54 million | -5.98 million | -6.45 million | -9.68 million |
| Depreciation | N/A | 94000 | -150000 | 221000 | 202000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | -178000 | 178000 | 178000 | 7000 | 7000 |
| Change to Net Income | 49.71 million | -11.85 million | -12.82 million | -1.38 million | -7.55 million |
| Capital Expenditures | N/A | 62000 | 114000 | 21000 | 61000 |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 239.64 million | N/A | 44.18 million | 52.7 million | 64.68 million |
| Total Stockholder Equity | -212.43 million | N/A | -34.99 million | -43.57 million | -54.54 million |
| Other Current Liabilities | 17.69 million | N/A | 18.79 million | 27.47 million | 38.59 million |
| Total Assets | 27.21 million | N/A | 9.18 million | 9.13 million | 10.15 million |
| Common Stock | 780000 | 722000 | 662000 | 614000 | 583000 |
| Other Current Assets | 2.93 million | N/A | N/A | 2.83 million | 2.6 million |
| Retained Earnings | -1.09 billion | -895.13 million | -837.18 million | -839.91 million | -846.58 million |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | 755000 | 753000 | 798000 | 753000 |
| Cash | 9.25 million | N/A | 764000 | 372000 | 1.97 million |
| Total Current Liabilities | 226.28 million | N/A | 39.66 million | 41.19 million | 53.42 million |
| Other Stockholder Equity | 333000 | 1.57 million | 1.87 million | 826000 | 2.01 million |
| Property, Plant & Equipment | 819000 | 5.93 million | 4.82 million | 5.13 million | 4.82 million |
| Total Current Assets | 12.18 million | N/A | 3.61 million | 3.2 million | 4.57 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | -214.37 million | -81.32 million | -34.99 million | -43.57 million | -54.54 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | 8.71 million | N/A | N/A | 6.59 million | 6.65 million |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 9.17 million | N/A | 8 million | 7.19 million | 7.4 million |
Northwest Biotherapeutics, Inc (NWBO) Chart:
Northwest Biotherapeutics, Inc (NWBO) News:
Below you will find a list of latest news for Northwest Biotherapeutics, Inc (NWBO) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Northwest Biotherapeutics, Inc (NWBO) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Northwest Biotherapeutics, Inc (NWBO) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1072379/000110465920080814/0001104659-20-080814-index.htm |
| 2019-10-28 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1072379/000000000019014919/0000000000-19-014919-index.htm |
| 2019-10-18 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1072379/000110465919054885/0001104659-19-054885-index.htm |
| 2019-10-18 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1072379/000110465919055013/0001104659-19-055013-index.htm |
| 2019-10-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1072379/000110465919056954/0001104659-19-056954-index.htm |
| 2019-10-29 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1072379/000110465919057265/0001104659-19-057265-index.htm |
| 2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1072379/000110465919062726/0001104659-19-062726-index.htm |
| 2019-12-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1072379/000110465919072581/0001104659-19-072581-index.htm |
| 2019-12-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1072379/000110465919075226/0001104659-19-075226-index.htm |
| 2020-01-03 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1072379/000110465920000953/0001104659-20-000953-index.htm |
| 2020-01-15 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1072379/000110465920004348/0001104659-20-004348-index.htm |
| 2020-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1072379/000110465920011526/0001104659-20-011526-index.htm |
| 2020-02-24 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1072379/000110465920024313/0001104659-20-024313-index.htm |
| 2020-03-16 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1072379/000110465920034145/0001104659-20-034145-index.htm |
| 2020-03-27 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1072379/000110465920039528/0001104659-20-039528-index.htm |
| 2020-04-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1072379/000110465920041889/0001104659-20-041889-index.htm |
| 2020-04-09 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1072379/000110465920045246/0001104659-20-045246-index.htm |
| 2020-04-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1072379/000110465920050392/0001104659-20-050392-index.htm |
| 2020-05-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1072379/000110465920055770/0001104659-20-055770-index.htm |
| 2020-05-12 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB | https://www.sec.gov/Archives/edgar/data/1072379/000110465920060182/0001104659-20-060182-index.htm |
| 2020-05-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1072379/000110465920064325/0001104659-20-064325-index.htm |
| 2020-05-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1072379/000110465920066499/0001104659-20-066499-index.htm |
| 2020-05-29 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1072379/000110465920067868/0001104659-20-067868-index.htm |
| 2020-06-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1072379/000110465920069884/0001104659-20-069884-index.htm |
| 2020-06-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1072379/000110465920070902/0001104659-20-070902-index.htm |
| 2020-06-12 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1072379/000110465920072809/0001104659-20-072809-index.htm |
| 2020-06-24 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1072379/000110465920076152/0001104659-20-076152-index.htm |
| 2020-06-24 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1072379/000110465920076154/0001104659-20-076154-index.htm |
| 2020-06-26 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1072379/000110465920077525/0001104659-20-077525-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1072379/000110465920080806/0001104659-20-080806-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1072379/000110465920080807/0001104659-20-080807-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1072379/000110465920080808/0001104659-20-080808-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1072379/000110465920080809/0001104659-20-080809-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1072379/000110465920080810/0001104659-20-080810-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1072379/000110465920080811/0001104659-20-080811-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1072379/000110465920080812/0001104659-20-080812-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1072379/000110465920080813/0001104659-20-080813-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1072379/000110465920080814/0001104659-20-080814-index.htm |
| 2020-08-07 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1072379/000110465920092026/0001104659-20-092026-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1072379/000110465920092797/0001104659-20-092797-index.htm |
| 2020-08-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1072379/000110465920097276/0001104659-20-097276-index.htm |
| 2020-09-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1072379/000110465920101343/0001104659-20-101343-index.htm |
| 2020-09-14 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1072379/000110465920104799/0001104659-20-104799-index.htm |
| 2020-09-15 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1072379/000110465920105286/0001104659-20-105286-index.htm |
| 2020-10-13 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1072379/000110465920114289/0001104659-20-114289-index.htm |
| 2020-10-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1072379/000110465920115717/0001104659-20-115717-index.htm |
| 2020-11-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1072379/000110465920120452/0001104659-20-120452-index.htm |
| 2018-12-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1072379/000114420418065727/0001144204-18-065727-index.htm |
| 2019-01-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1072379/000114420419003609/0001144204-19-003609-index.htm |
| 2019-02-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1072379/000114420419005630/0001144204-19-005630-index.htm |
| 2019-03-19 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | https://www.sec.gov/Archives/edgar/data/1072379/000114420419014880/0001144204-19-014880-index.htm |
| 2019-04-02 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1072379/000114420419017803/0001144204-19-017803-index.htm |
| 2019-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1072379/000114420419025347/0001144204-19-025347-index.htm |
| 2019-05-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1072379/000114420419028330/0001144204-19-028330-index.htm |
| 2019-07-17 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1072379/000114420419034953/0001144204-19-034953-index.htm |
| 2019-07-18 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1072379/000114420419034974/0001144204-19-034974-index.htm |
| 2019-07-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1072379/000114420419035392/0001144204-19-035392-index.htm |
| 2019-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1072379/000114420419038889/0001144204-19-038889-index.htm |
| 2019-01-08 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1072379/000117494719000010/0001174947-19-000010-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1072379/000121390019002518/0001213900-19-002518-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1072379/000121390019002524/0001213900-19-002524-index.htm |
| 2019-10-31 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1072379/999999999519002446/9999999995-19-002446-index.htm |
Northwest Biotherapeutics, Inc (NWBO) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Northwest Biotherapeutics, Inc (NWBO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 396%Institutional Ownership: 3%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-12-28 | Linda F Powers | President and CEO | Sell | 804,146.00 | 0.17 | 136,704.82 | 0.00 | https://www.sec.gov/Archives/edgar/data/1072379/000114420419003609/0001144204-19-003609-index.htm |
| 2020-02-03 | JERRY J JASINOWSKI | Director | Buy | 526,316.00 | 0.19 | 100,000.04 | 1,891,347.00 | https://www.sec.gov/Archives/edgar/data/1072379/000110465920011526/0001104659-20-011526-index.htm |
| 2018-12-27 | Linda F Powers | President and CEO | Sell | 3,558,639.00 | 0.17 | 604,968.63 | 29,411,760.00 | https://www.sec.gov/Archives/edgar/data/1072379/000114420419003609/0001144204-19-003609-index.htm |